Drugs / SAR342434
SAR342434
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02603510 | Nov 2015 → Apr 2016 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02273258 | Mar → Jul 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02294474 | Jan 2015 → Feb 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02273180 | Oct 2014 → Dec 2015 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR342434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02273180 ↗ |
| Known as | insulin lispro | “BACKGROUND: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis).” PMID 29359575 ↗ Jan 2018 |
| Known as | SAR-Lis | “BACKGROUND: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis).” PMID 29359575 ↗ Jan 20181“BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog®; Ly-Lis).” PMID 29232162 ↗ Dec 2017 |
| Modality | Protein / enzyme biologic | “BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro” PMID 29232162 ↗ Dec 2017 |
| Route | Subcutaneous | “self-administered by deep subcutaneous (SC) injection” NCT02273180 ↗ |